A Vaccine for a Mosquito-Borne Disease Fuels Valneva Stock Rally

After a torrid few years, Valneva SE shares have rallied hard in 2025, and judging by analysts’ projections there may be more to come as the French vaccine maker benefits from diseases stoked by climate change.

The stock has more than doubled this year, bouncing back from a post-pandemic plunge. The bulk of the gain took place this quarter, and analysts are optimistic it can be extended, with the average price target implying a further 62% upside.